Three Under-the-Radar Stocks Hiding in Plain Sight While Everyone Argues About Iran

Here's the thing about market chaos: it's the perfect camouflage. While every financial pundit on Bloomberg is debating whether the Hormuz blockade is a throwdown the US can't win, a handful of small-cap companies are building real businesses that almost nobody is covering. Let's fix that.

$CLFD (Clearfield Inc.) is a fiber-optic connectivity infrastructure company — think picks-and-shovels for broadband buildout — with a market cap around $500M. It's been battered down from its 2022 highs as the BEAD program funding rollout slowed, but that money is now starting to flow. The catalyst? Federal broadband infrastructure grants are finally hitting the deployment phase, and Clearfield is a direct beneficiary with its FieldSmart fiber management systems already spec'd into rural network builds across 48 states. Reddit's r/smallcapstocks has had sporadic DD threads calling it a BEAD lottery ticket with actual revenue.

$RCKT (Rocket Pharmaceuticals) sits in the rare disease gene therapy space with a market cap under $1.5B — tiny for biotech. Its lead program targets Fanconi anemia, a devastating pediatric bone marrow disorder with zero approved treatments. The FDA granted it Breakthrough Therapy designation, and a BLA filing window is approaching. Meanwhile, $TBPH (Theravance Biopharma) is a respiratory-focused biotech spinning its royalty streams into pure cash flow — trading near book value with a $900M market cap — and YouTube's biotech deep-dive community has been quietly flagging its undervalued royalty on GSK's Trelegy as a potential buyout magnet. Three different stories, one common thread: nobody's paying attention yet.

The best time to find hidden gems is when the whole room is looking the other way — and right now, the whole room is watching warships.